Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 6/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.45 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848983 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNA7CYP2A6CYP2C19 | |
| SCHEMBL5849240 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNA7CYP2A6CYP2C19 | |
| SCHEMBL5848679 | 0.82 | CYP19A1 (0.42) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL5848685 | 0.82 | CYP19A1 (0.42) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL5849142 | 0.82 | CYP19A1 (0.42) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL5848637 | 0.81 | GRM5 (0.36) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL5848632 | 0.81 | GRM5 (0.36) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL5849247 | 0.81 | GRM5 (0.36) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL7695321 | 0.80 | LTA4H (0.42) | CHRNB2CHRNA4CHRNA7KMT2APOLB | |
| SCHEMBL7695323 | 0.80 | LTA4H (0.42) | CHRNB2CHRNA4CHRNA7KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101896-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2006-09-05 | — | — | US | claimed |
| US-6890935-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2005-05-10 | — | — | US | claimed |
| WO-2002088114-A2 | HETEROARYL OFEFINIC AZACYCLIC AND HETEROARYL ACETYLENIC AZACYCLIC COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | TARGACEPT, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-05-16 | — | — | US | claimed |
| US-7101896-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050267111-A1 | Pharmaceutical compositions and methods for use | DULL GARY M | 2005-12-01 | — | — | US | disclosed |
| US-6890935-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| WO-2002088114-A2 | HETEROARYL OFEFINIC AZACYCLIC AND HETEROARYL ACETYLENIC AZACYCLIC COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | TARGACEPT, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| EP-1225955-A1 | ARYL OLEFINIC AZACYCLIC, AND ARYL ACETYLENIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2001032264-A1 | ARYL OLEFINIC AZACYCLIC, AND ARYL ACETYLENIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267111-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | CHRNB2 723/4885CHRNA4 367/4885CHRNA7 259/4885 |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | CHRNB2 723/4885CHRNA4 367/4885CHRNA7 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.